Enhancing the anti-cancer potential of resveratrol through cocrystal technology in colorectal cancerous rats Authors: Durga Polati, Prasad Neerati Published: 2025 ABSTRACT Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, and the limitations of current chemotherapeutic regimens necessitate alternative therapeutic approaches. Resveratrol (RES) possesses potent anticancer activity but suffers from poor solubility and low bioavailability. In this study, cocrystallization with quercetin (QUE) was employed as a strategy to overcome these limitations and enhance the therapeutic performance of RES. Resveratrol–Quercetin cocrystals (RES–QUE CoCry) were prepared by the solvent evaporation method to enhance physicochemical and pharmacokinetic properties. The cocrystals exhibited a novel crystalline phase with a 2-fold increase in solubility at pH 6.8 and a 2.64 fold increase in permeability compared to pure RES. Pharmacokinetic analysis showed a 3.2fold increase in Cmax and a 3.5fold rise in AUC0-24 h, confirming enhanced bioavailability. In N-methyl-N-nitrosourea (MNU) induced CRC rat model, RES–QUE CoCry treatment restored epithelial integrity, reduced inflammation. qRTPCR and western blot analysis showed down regulated BCL2 expression, indicating potentiated pro-apoptotic activity. By this study, it was proved that cocrystallization of RES with QUE enhances both bioavailability and in-vivo anticancer efficacy, offering a novel phytochemical-based strategy for CRC management.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28307-9. Introduction Colorectal cancer (CRC) remains a significant global health concern, ranking second in mortality and third in incidence among cancers worldwide1. In 2022 alone, CRC was responsible for approximately 1.9 million new cases and over 900,000 deaths globally2. The disease often progresses silently, with symptoms appearing only in advanced stages, limiting treatment options and significantly reducing survival rates3. Early detection and innovative therapeutic strategies are essential to improve patient outcomes4. One of the primary hallmarks of CRC is the dysregulation of apoptotic pathways, which allows malignant cells to evade programmed cell death and continue proliferating5. Many anticancer treatments, including chemotherapy, aim to reactivate apoptosis in cancer cells. However, conventional chemotherapy is often hindered by severe side effects, drug resistance, and non-selective cytotoxicity, which limits its long-term efficacy. Consequently, there is growing interest in developing safer and more effective therapeutic approaches, particularly those based on bioactive dietary compounds dietary combinations, or a combination of natural agents and anticancer medication6. As a result, natural bioactive compounds with targeted apoptotic activity and minimal side effects have gained considerable interest in cancer therapy7. Among these compounds, resveratrol (RES), a polyphenol abundant in grapes, berries, and peanuts, has shown potent anti-cancer properties8,9. Preclinical studies suggest that RES promotes apoptosis byup regulating pro-apoptotic proteins such as Bax while down regulating anti-apoptotic proteins like BCL-2, thereby disrupting cancer cell survival mechanisms10. The response of certain malignancies to RES treatment has been investigated. It has shown that to induce apoptosis in lung and colon cancer cell lines, RES increases the expression of Bax and caspase-3 while decreasing the BCL-2 and BCL-2/Bax ratio in a dose and time dependent manner11. Although RES has potent anti-cancer properties, its clinical use is limited due to poor bioavailability caused by rapid metabolism and elimination12. It is rapidly metabolized by liver and intestines into various compounds that maintain limited intrinsic action, including resveratrol 3-O-glucuronide, resveratrol 4-O-glucuronide, and resveratrol trisulphate13. A promising strategy to enhance RES bioavailability is co-administration with quercetin (QUE), a flavonoid known for its antioxidant, anti-inflammatory, and anti-cancer properties14. QUE inhibits UDP-glucuronosyl transferases (UGTs) and sulfotransferases (SULTs), key enzymes responsible for RES metabolism, thereby reducing its conversion into inactive forms and increasing its systemic availability15. RES is subject to efflux by transport proteins such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which limits its absorption and retention in cells16. QUE acts as an inhibitor of these transporters, reducing RES efflux and promoting its intracellular accumulation17. Studies have demonstrated that QUE enhances RES-mediated apoptosis by increasing caspase-3 activation and modulating key apoptotic pathways more efficiently than either compound alone18. Additionally, the combination of RES and QUE has been found to improve histological outcomes and suppress CRC cell proliferation cancer19.From the crystal engineering perspective, QUE offers exceptional molecular compatibility with RES owing to complementary hydrogen-bond donor/acceptor sites, strong π–π stacking potential between aromatic systems, and favorable steric complementarity. Such a combination has not been matched by literature-reported polyphenolic coformers, making QUE the most rational choice for improving both physicochemical and biological performance of RES. Based on this rationale, the present work aimed to synthesize the resveratrol–quercetin cocrystal (RES–QUE CoCry) via cocrystallization, a proven strategy to enhance solubility, dissolution rate, and solid-state stability through non-covalent interactions20. The synthesis of RES-QUE CoCry has not been reported yet in the literature. This study pioneers the synthesis of a RES-QUE cocrystal, which is expected to significantly improve RES stability, solubility, therapeutic efficacy, and thereby potentiating its anticancer effects in CRC treatment. Materials and methods Chemicals and equipment Resveratrol (purity > 99.8%), quercetin (99%) were purchased from Sigma–Aldrich (Vasudha enterprises, Hyderabad, India), N-Methyl Nitraso Urea purchased from synchem labs (Hyderabad, India). Trizol Reagent (Thermo Scientific), Chloroform (Sigma-Aldrich), Isopropanol (Sigma-Aldrich), 75% Ethanol (RNase-free), RNase-free Water, DBase I Kit (Qiagen or Invitrogen) (for genomic DNA removal), NanoDrop Spectrophotometer & 1.5% Agarose Gel (for RNA quality check).SYBR Green Master Mix (SensiFAST SYBR Hi-Rox, Bioline, USA), Quant Studio 3 (Thermo Fisher) qPCR System, Validated Primers for BCL2 & GAPDH. Solvents (purity > 99%) were purchased from Merc (Hyderabad, India). Molecular docking studies In this study, the molecular docking procedure for evaluating the cocrystal formation potential of RES and QUE was done by AutoDock 4.221. The structures of ligands in SDF format were converted to PDB format using Open Babel22. The ligands were processed in AutoDockTools (ADT) by adding polar hydrogen atoms, assigning Gasteiger charges, and defining torsional degrees of freedom. The prepared ligand structures were saved in PDBQT format. The docking grid was generated using the quercetin molecule as the reference (macromolecule: que.pdbqt), with the grid center positioned at coordinates (x = 0.086, y = 0.654, z = − 0.578). The grid dimensions were set to 60 × 50 × 40 points along the X, Y, and Z axes, respectively, with a grid spacing of 0.375 Å, covering coordinate ranges from (–11.164, − 8.721, − 8.078) to (11.336, 10.029, 6.922). The Lamarckian genetic algorithm was applied with a population size of 150, 2.5 × 10⁶ energy evaluations, and 50 independent runs. Energy maps were generated using Auto Grid to calculate interaction potentials23. Molecular docking was performed using AutoDock 4.2 with the Lamarckian genetic algorithm (LGA). The docking results were analyzed based on binding energy (ΔG in kcal/mol), molecular interactions (hydrogen bonds, π-π stacking, hydrophobic interactions), and complex stability. Preparation of resveratrol and quercetin cocrystals The synthesis of resveratrol and quercetin cocrystals (RES-QUE CoCry) was done by taking RES and QUE in a 1:1 mol ratio (RSV: 22.82 mg, 0.1 mmol; QUE: 30.22 mg, 0.1 mmol), were dissolved in 20mL of acetone and hexane mixture (1:1, v/v). Acetone served as the primary solvent for complete dissolution of both coformers, while hexane acted as a non-polar ant solvent to control super saturation and promote co-nucleation. The solution, containing RES and QUE, was allowed to stir for 24 h at 200 r.p.m speed using magnetic stirrer to facilitate cocrystal formation. The resulting solution was then subjected to slow evaporation under ambient conditions (20–25 °C). Crystals obtained were recrystallized in minimal acetone with gradual hexane addition, yielding well-defined spherical cocrystals after one week, which were dried under vacuum and stored in airtight containers. Characterization studies Fourier transform infrared spectroscopy For the identification and characterization of functional groups, the absorption spectra of cocrystals (RES-QUE CoCry) and raw components (RES, QUE and RES-QUE) in the infrared region were obtained using an Agilent Technologies-Cary 600 Series FTIR Spectrometer, by potassium bromide pellet method. The absorption spectrum of the samples was recorded between 4000 and 500 cm−1 with a resolution of 2 cm[- [1averaging 32 scans per sample24. Thermal analysis To observe the changes in the melting point imposed by cocrystallization, differential scanning calorimetry (Perkin Elmer DSC 8000) measurements were carried out for RES, QUE, RES-QUE and RES-QUE CoCry.5–10 mg of the ground material was added to an aluminum pan. The sampled non-hermetic pans were heated from 40 to 300 °C at a rate of 10 °C min−1under atmosphere of dry nitrogen (60 ml min−1)25. Powder x-ray diffraction studies Powder X-ray Diffraction (PXRD) data obtained using an X’Pert powder PAN analytical X-ray diffractometer with Cu kα (λ = 1.5418 Aº) produced at 30 kV and 10 mA. RES, QUE, RES-QUE and RES-QUE CoCry samples were positioned on silicon disks, and measurements were made within an angular range of 5–50 º (2θ) with a dwell time of 0.1s and a step size of 0.01142 º (2θ)26. Scanning electron microscope analysis Using a scanning electron microscope (SEM, S-4800, Hitachi Ltd., Tokyo, Japan), the surface morphology of RES, QUE, RES-QUE and CoCry were examined. Samples were sputter-coated with gold prior to imaging. SEM micrographs were analyzed to assess particle shape, size distribution, and surface texture27. Nuclear magnetic resonance (NMR) spectroscopy Nuclear Magnetic Resonance (NMR) spectroscopy was performed to analyze the samples using CDCl3 as the solvent and tetramethylsilane (TMS) as an internal standard. The solution-state NMR spectra were acquired at 293 K using a BrukerAvance AV 400 spectrometer (BrukerBioSpin Corp., Massachusetts, USA). Data processing was conducted using TopSpin software (BrukerBioSpin Corp., Massachusetts, USA).For solid-state NMR (ssNMR) measurements, a Bruker Avance AV 400 spectrometer was used, equipped with a Bruker 4 mm double resonance magic angle spinning (HR-MAS) probe. The 1H ssNMR spectra were recorded using a 90° pulse length of 2.5 µs, with 8 scans acquired for signal averaging. 13C cross-polarization magic-angle spinning (CP/MAS) spectra were obtained at a spinning speed of 14 kHz28. Drug content analysis Drug content analysis was done by taking 5 mg of RES-QUE CoCry (equivalent to pure RES), dissolved in 5 ml of methanol and allowed to 15 min of ultrasonication. The sample solution was subjected to centrifugation at 10,000 rpm for 10 min. The solution was filtered, collected supernatant, diluted as required and then subjected to HPLC analysis The calibration curve was constructed with known concentrations, prepared from stock solution of RES(1 mg/ml).A Shimadzu HPLC system (Shimadzu, Tokyo, Japan) consisting of an SPD-20 A ultraviolet–visible (UV/VIS) detector was used in this study. The Analysis was done by following previously reported method with little modification, on phenomenex, C18 column (250 mm x 4.6 mm, 5 μm), using a mobile phase comprised of acetonitrile and 0.1% orthophosphoric acid in a 55:45 (v/v) ratio, 1mL/min flow rate, 30 °C column temperature, 20 µL injection volume, and UV detector wavelength of 307 nm29. Solubility studies The solubility test was performed by taking an excess amount (20 mg/L) RES, equivalent weight of RES-QUE CoCry in phosphate buffer solution (pH 6.8) and 0.1 m HCL (pH 1.2)30. After 10 min of ultrasonic shaking, the solutions were stirred at 100 rpm, maintained at 37 °C for 24 h using magnetic stirrer (REMI). Then the 1 mL suspension was taken from that and centrifuged at 10,000 rpm for 10 min. The supernatant was filtered through the 0.22 μm nylon filter and the collected supernatant is subjected to HPLC analysis. Above studies were conducted in triplicate. While the remaining solids after filtration were analyzed by PXRD to identify their solid state form. Dissolution studies Dissolution study was conducted following paddle-type dissolution equipment (USP II) with a paddle speed of 100 rpm at 37 °C for 2 h. 0.1 N HCL (pH 1.2) and phosphate buffer solution (pH 6.8) were used as dissolution medium. 50 mg of RES, equivalent weight of RES-QUE CoCry was placed in 900 mL of dissolution medium. At specified points of time, a volume of 1mL of sample was withdrawn from dissolution medium and each time 1mL of fresh medium was added in order to maintain the volume at 900 mL. Subsequent to a 10-minute centrifugation at 10,000 rpm, the samples were examined utilizing the supernatants and filtered using a 0.10 μm filter. Dissolution test was carried out in triplicate for each sample31. The concentration of dissolved RES was determined by HPLC analysis. Permeability studies by everted sac method The everted-gut sac method was used to determine the apparent permeability coefficient (Papp) of the RES-QUE CoCry in comparison to the RES and RES-QUE. A reported method was followed for the study32. In brief, 2 mL of the physiological buffer (Tyrode’s solution) was introduced to the sac (on the serosal side) of the rat intestine after it had been everted. This buffer-filled everted sac was submerged in 50 ml of physiological buffer that contained the fixed amounts (equivalent to 10 mg) of RES, RES-QUE, and RES-QUE CoCry. The complete set up was kept in a bath at 37° ± 5 °C with continuous aeration to the physiological fluid (on the mucosal side) carrying the drug sample. At predetermined time points (5, 10, 20, 30, 60, 90, and 120 min) 1 mL of the solution from the sac (serosal side) was taken for analysis and replaced with fresh pre-warmed Tyrode’s solution each time to maintain sink conditions and osmotic balance. The collected sample was filtered, and the amount of RES that had permeated was measured. The total study was performed in triplicate. Stability studies Stability testing of the RES–QUE CoCry was performed in accordance with the principles outlined in the ICH Q1A (R2) guideline for stability testing of new drug substances and products (ICH, 2003), adapted for solid-state characterization of cocrystals. The RES-QUE CoCry sample was placed in a well closed glass vial and kept at room temperature (25 ± 2 °C) in a desiccator for a period of 3 months. PXRD studies were carried out three months later to verify the stability of cocrystals. PXRD was used to identify the solid phase transition due to the moisture uptake, and the diffraction pattern of cocrystals after three months was examined and compared33. Pharmacokinetic study The animal study protocol is in compliance with institutional guidelines for the care and use of laboratory animals. The protocol for all in-vivo animal experiments was approved by Institutional Animal Ethical Committee, Kakatiya University, Warangal (11/IEAC/UCPSC/KU/2022: CCSEA 2018-23). To investigate the oral bioavailability of RES-QUE CoCry, the in-vivo pharmacokinetics of resveratrol in male Wistar rats were performed. Eighteen male Wistar rats (200 ± 10 g) were divided into three treatment groups of six rats each. The three experimental groups received 10 mg/kg b.wt of RES, equivalent weight of RES-QUE and RES-QUE CoCry in 1% Carboxy Methyl Cellulose orally. Blood samples (approximately 0.5mL) were collected in heparinized tubes by retro orbital puncture of the treated rats at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 and 24 h after dosing. Blood samples were centrifuged at 12,000 × g for 10 min at 4 °C. The amount of RES in plasma was determined using HPLC, following a previously reported analytical method with slight modifications29. Calibration curve was constructed by taking 100 µL of rat plasma, 100 µL of IS carbamazepine (50 µg/mL) and 100 µL of RES and the mixture was incubated at 37 ° C for 1 h. RES was then extracted using 200 µL of cold acetonitrile (liquid–liquid extraction; LLE) followed by vortexing for 2 min. After vortexing, the samples were subjected to centrifuge at 12,000 g for 15 min using cold centrifuge (Biofuge primo R). Supernatant was subjected to HPLC for analysis. Data were then used to determine the maximum plasma concentration of RES (Cmax), and the time required to reach Cmax (Tmax ) and the area under the plasma concentration versus time curve (AUC0→24 h) were calculated . Anti-cancer activity of cocrystals 30 male Wistar rats (Age: 5–8 weeks, weighing about 180-200gm) were housed under standard laboratory settings, with a temperature of 24–27 °C, in cages made of polyacrylic. Rats were randomly allocated in to five groups. Control-given 0.5 ml of normal saline intra rectally; MNU model group- received an intra-rectal instillation of MNU solution (0.5 mL, 10 mg/kg) three times a week for 5 weeks34; MNU + RES group- received an intra-rectal instillation of MNU solution (0.5 mL, 10 mg/kg) three times a week for 4 weeks and oral administration of 10 mg/kg of RES in suspension of 0.5% of CMC35;MNU + RES-QUE group- received an intra-rectal instillation of MNU solution (0.5 mL, 10 mg/kg) three times a week for 5 weeks and oral administration of 10 mg/kg of physical mixture of RES and QUE in suspension of 0.5% of CMC; MNU + RES-QUE CoCry group received an intra-rectal instillation of MNU solution (0.5 mL, 10 mg/kg) three times a week for 5 weeks and oral administration of 10 mg/kg of RES-QUE CoCry in suspension of 0.5% of CMC. Animals were kept at animal facility under standard temperature and humidity conditions. At the end of the experimental period, animals were humanely euthanized in accordance with CPCSEA guidelines. First, deep anesthesia was induced via an intra peritoneal injection of ketamine (80 mg/kg) and xylazine (10 mg/kg). After loss of consciousness and suppression of reflexes, a secondary physical method (cervical dislocation) was performed to ensure death and colon were removed surgically from each animal and part of it fixed in 10% phosphate buffered formalin and submitted for histopathology. Other tissues were frozen for further analysis. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) RNA isolation from rat colon tissue was performed by using Trizol (Thermo Scientific) by following the manufacturer’s protocol. The integrity of isolated RNA was checked on agarose gel (1.5% w/v). Preparation of cDNA was done by using Prime Script™ 1st strand cDNA Synthesis Kit by following the manufacturer’s protocol. 2 µg total RNA along with the equal amount of random hexamers and oligodT primers were used for synthesis of cDNA. cDNA synthesis was carried out at 42 °C and enzyme inactivation was done at 95 °C. The primer sequences were found to be with the expression of BCL2 related to the forward sequence is 5′- GTACCTGAACCGGCATCTG − 3′ and the reverse sequence found as to with the following sequence like 5′- GGGGCCATATAGTTCCACAA − 3′. The primer sequence of GADPH was found to be forward sequence with 5′- AGACAGCCGCATCTTCTTGT − 3′ and the reverse sequence is with as 5′- TGATGGCAACAATGTCCACT − 3′. Genes were amplified by PCR (T100 Thermo cycler, Bio-Rad, USA). The specificity of each primer pair was validated by melt curve analysis, confirming the amplification of a single, target-specific product without non-specific peaks or primer-dimer formation. Relative gene expression was calculated using the ΔCq method, normalizing BCL2 expression to GAPDH. Western blot analysis Proteins were extracted from rat colon tissue using cold RIPA (Radio immune precipitation Assay) buffer, and the lysate was clarified by centrifugation at 10,000×g for 5 min at 4 °C and the supernatant containing soluble proteins was collected. Protein concentration was determined using a calibration curve. For SDS-PAGE, 10–50 µg of protein was mixed with loading buffer, heated at 95 °C for 10 min, and loaded onto a 10% gel. After electrophoresis, proteins were transferred to a methanol-activated PVDF (Polyvinylidene Difluoride) membrane at 25 V for 60 min, and transfer efficiency was checked using Ponceau staining. The membrane was blocked with 3% Bovine Serum Albumin, (for phosphoproteins) or 5% defatted dried milk (for non-phosphoproteins) for 1 h, followed by incubation with a primary antibody (1:1000) overnight and a secondary antibody (1:2000) for 1.5 h, with PBS-T (Phosphate buffer saline with Tween-20) washes in between. Bounded secondary antibody was detected by using ECL (Enhanced Chemiluminescence) detection reagent. Images captured images in Gel Documentation system (CamagReprostar 3) and developed blot was analyzed36. The membrane was cut horizontally prior to primary antibody incubation to facilitate simultaneous probing for proteins of different molecular weights. Images captured images in Gel Documentation system (CamagReprostar 3) and developed blot was analyzed36. Densitometric analysis was performed using ImageJ. Full-length, uncropped images of all membranes, including visible membrane edges for all replicates performed in this study, are provided in the Supplementary Information file. Results Molecular Docking studies The docking results revealed that both molecules adopt complementary binding conformations, with their interactions predominantly stabilized by strong hydrogen bonds and favorable π-π stacking. Hydrogen bond distances were observed in the range of 1.8–2.5 Å, indicative of robust intermolecular interactions, while the absence of significant steric hindrance supports a good geometric compatibility among then RES and QUE. Although the overall binding energies were moderate (approximately − 2.85 kcal/mol), the combined effect of these interactions suggests that the molecular complementarity of RES and QUE is conducive to forming a stable cocrystal. Docking poses are presented (Fig. 1). Fig. 1Molecular docking poses ofresveratrol (gray color) and quercetin (green color) and inter molecular hydrogen bands are represented by dashed lines. Molecular docking poses ofresveratrol (gray color) and quercetin (green color) and inter molecular hydrogen bands are represented by dashed lines. Characterization studies Fourier transform infrared spectroscopy The FTIR spectra of pure RES, pure QUE, and their cocrystal were recorded to confirm intermolecular interactions. In the spectrum of RES, the broad absorption at 3161 cm−1 corresponded to the O-H stretch, while the aromatic − C = C − stretching vibrations appeared at 1583.4 cm−1, 1499 cm−1, and 1441.97 cm−1. Peaks at 1583.43 cm−1, 1144.12 cm−1, and 965.23 cm−1 were attributed to C − O stretching, olefinic C − C stretching, and trans-olefinic bending vibrations, respectively. For QUE, a characteristic band at 3391 cm−1 was assigned to free O-H bond vibration, while the C = O stretching vibrations appeared at 1662 cm−1and 1603 cm−1. The aromatic ring vibrations were observed at 1517 cm−1 and 1452 cm−1, along with C-O-C vibrations at 1309 cm−1 and 1164 cm−1. In the FTIR spectrum of the cocrystal, key spectral changes indicated interactions between RES and QUE. The phenol O-H stretching vibration of RES at 3161.12 cm−1 disappeared, suggesting hydrogen bond formation. The O-H stretching and C = O stretching bands of QUE shifted to 3215 cm−1 and 1656.48 cm−1, respectively. Additionally, the C = C aromatic stretching band shifted to 1597 cm−1, and the C = C olefinic bond stretching appeared at 1504 cm−1. These spectral shifts were absent in the individual spectra of RES and QUE, confirming the formation of the cocrystal and the presence of intermolecular interactions. These changes were not reflected in spectrum of RES-QUE (Fig. 2). Fig. 2Fourier-transform infrared (FTIR) spectra of RES (pure resveratrol), QUE (pure quercetin), RES-QUE (physical mixture), and RES-QUE CoCry (cocrystal of resveratrol and quercetin), showing characteristic shifts in the O–H and C = O stretching regions indicative of intermolecular hydrogen bonding in the cocrystal. Fourier-transform infrared (FTIR) spectra of RES (pure resveratrol), QUE (pure quercetin), RES-QUE (physical mixture), and RES-QUE CoCry (cocrystal of resveratrol and quercetin), showing characteristic shifts in the O–H and C = O stretching regions indicative of intermolecular hydrogen bonding in the cocrystal. Thermal analysis As cocrystallization affects the melting point, differential scanning calorimetry was used to assess cocrystal formation. DSC curves of RES, QUE, RES-QUE, and RES-QUE CoCry are shown (Fig. 3). The DSC thermogram of pure RES exhibited two endothermic peaks: one at 254.12 °C, and another at 126.4 °C. The thermogram of QUE powder showed two peaks at 323.1 °C as well as 135.8 °C. The DSC curve for the RES-QUE physical mixture showed an endothermic peak at 256.52 °C.DSC of RES-QUE CoCry displayed a single endothermic event at 268.10 °C that was distinct from the melting temperatures of RES, QUE, and RES-QUE (Fig. 3). Fig. 3Differential scanning calorimetry (DSC) thermograms of RES (pure resveratrol), QUE (pure quercetin), RES-QUE (physical mixture), and RES-QUE CoCry (cocrystal of resveratrol and quercetin), demonstrating distinct melting behavior of the cocrystal compared to individual components and the physical mixture, consistent with a new solid-state structure. Differential scanning calorimetry (DSC) thermograms of RES (pure resveratrol), QUE (pure quercetin), RES-QUE (physical mixture), and RES-QUE CoCry (cocrystal of resveratrol and quercetin), demonstrating distinct melting behavior of the cocrystal compared to individual components and the physical mixture, consistent with a new solid-state structure. Powder x-ray diffraction studies The diffractograms of RES, QUE, RES-QUE and RES-QUE CoCry were shown (Fig. 4). PXRD pattern of RES showed characteristic peaks at 2θ values of 6.5°, 16.3°, 19.12°, 22.3°, 23.0°, 23.5°, 24.1°, 25.2°, 28.2.° and 32.0°. QUE showed specific strong peaks at 2θ values of 6.28°, 10.8°, 12.43°, 15.7°, 23.8°, and 27.38°. The characteristic diffraction peaks of the physical mixture of RES-QUE are equivalent to the superimposed peaks of RES and QUE. RES-QUE CoCry phase showed diffraction profile with stretching of peaks at 2θ values of 6.6°, 10.72°, 12.4°, 14.2°, 16.35°, 19.1°, 22.3°, 23.5°, 24.3°, 27.3°, 28.26°and 30.4°. PXRD result indicates change in crystal lattice due to interaction between RES and QUE to form a new phase. Fig. 4Powder X-ray diffraction (PXRD) patterns of RES (pure resveratrol), QUE (pure quercetin), RES-QUE (physical mixture), and RES-QUE CoCry (cocrystal of resveratrol and quercetin, highlighting the disappearance of parent peaks and appearance of new reflections confirming cocrystal formation. Powder X-ray diffraction (PXRD) patterns of RES (pure resveratrol), QUE (pure quercetin), RES-QUE (physical mixture), and RES-QUE CoCry (cocrystal of resveratrol and quercetin, highlighting the disappearance of parent peaks and appearance of new reflections confirming cocrystal formation. SEM analysis SEM analysis was done for RES, QUE, RES-QUE and RES-QUE CoCry (Fig. 5). SEM analysis revealed that morphology of crystals from pure compounds, physical mixture and cocrystals. It can be observed that crystal habit of RES like rod shape while QUE like needle shaped, Moreover, the morphology of physical mixture was a combination of RES and QUE, while the morphology of cocrystal was different in which the crystal size reduced and unique crystal growth compared to both pure RES and QUE. Fig. 5Scanning electron microscopy (SEM) images of (A) pure resveratrol, (B) pure quercetin, (C) physical mixture of resveratrol and quercetin, and (D) RES-QUE CoCry (cocrystal of trans-resveratrol and quercetin), revealing distinct morphological transformation in the cocrystal compared to the parent compounds and their physical mixture. Scanning electron microscopy (SEM) images of (A) pure resveratrol, (B) pure quercetin, (C) physical mixture of resveratrol and quercetin, and (D) RES-QUE CoCry (cocrystal of trans-resveratrol and quercetin), revealing distinct morphological transformation in the cocrystal compared to the parent compounds and their physical mixture. NMR analysis Molecular interactions were indicated by the notable chemical shift fluctuations in the13C NMR spectra of the RES-QUE CoCry (Fig. 6A) when compared to pure RES and QUE. The standard NMR data for RES and QUE was obtained from reported studies, which served as a reference for identifying chemical shifts and interactions in the cocrystal. Stronger hydrogen bonding at the carbonyl site is suggested by the downfield shift of the carbonyl (C = O) peak at 175.98 ppm in comparison to the reported 175.2 ppm in QUE. Intermolecular interactions that modify the electrical environment are further supported by the finding that hydroxyl (-OH) attached carbons at 156.59 ppm and 164.16 ppm showed deviations from their standard values in QUE (156.2 ppm and 164.8 ppm, respectively). There were also slight changes in the aromatic C-OH area, with maxima at 145.15 ppm (compared to 144.5 ppm in RES) and 147.73 ppm (compared to 148.3 ppm in QUE). These modifications show structural stabilization brought on by intermolecular hydrogen bonding and electron delocalization. Fig. 6Nuclear magnetic resonance (NMR) spectra of RES-QUE CoCry (cocrystal of resveratrol and quercetin): (A) solution-state13C NMR, (B) solution-state1H NMR, and (C) solid-state NMR.Nuclear magnetic resonance spectra of resveratrol and quercetin cocrystal. Nuclear magnetic resonance (NMR) spectra of RES-QUE CoCry (cocrystal of resveratrol and quercetin): (A) solution-state13C NMR, (B) solution-state1H NMR, and (C) solid-state NMR.Nuclear magnetic resonance spectra of resveratrol and quercetin cocrystal. The 1H NMR spectra (Fig. 6B) of the cocrystal further validate these interactions. The hydroxyl (-OH) protons (12.50, 10.91, and 9.53 ppm) exhibited down field shifts compared topure RES (9.51 ppm) and QUE (12.48, 10.89 ppm) confirming strong hydrogen bonding within the cocrystal. Additionally, aromatic protons (6.2–8.0 ppm) showed minor shifts, supporting π-π stacking, which aligns the aromatic rings of RES and QUE in an optimized conformation. The chemical shifts from NMR spectra were tabulated (Table 1). Table 1Summarized chemical shifts from NMR spectra of RES-QUE cocry in comparison to spectral values of RES and QUE.NMR analysisPeak (δ, ppm) in RESPeak (δ, ppm) in QUEPeak (δ, ppm) in RES-QUE CoCryShift observation13C NMR-175.2 (Carbonyl carbon)175.98Shifted downfield-164.8(hydroxyl carbon)164.16Shifted Upfield-156.2(hydroxyl carbon)156.59Shifted downfield144.5 (Aromatic C-OH Region)–145.15Minor shift1H NMR9.51 (Hydroxyl –OH)12.48, 10.89(Hydroxyl–OH)12.50, 10.91, 9.53–6.2–7.5(Aromatic protons)6.0–8.0 (QUE6.2–8.0– Table 1Summarized chemical shifts from NMR spectra of RES-QUE cocry in comparison to spectral values of RES and QUE.NMR analysisPeak (δ, ppm) in RESPeak (δ, ppm) in QUEPeak (δ, ppm) in RES-QUE CoCryShift observation13C NMR-175.2 (Carbonyl carbon)175.98Shifted downfield-164.8(hydroxyl carbon)164.16Shifted Upfield-156.2(hydroxyl carbon)156.59Shifted downfield144.5 (Aromatic C-OH Region)–145.15Minor shift1H NMR9.51 (Hydroxyl –OH)12.48, 10.89(Hydroxyl–OH)12.50, 10.91, 9.53–6.2–7.5(Aromatic protons)6.0–8.0 (QUE6.2–8.0– Summarized chemical shifts from NMR spectra of RES-QUE cocry in comparison to spectral values of RES and QUE. The13C CP/MAS SSNMR spectra (Fig. 6C) provided further evidence supporting cocrystal formation. In the solid-state spectrum, the carbonyl peak at 173.94 ppm shown downfield shift from173.791 ppm (QUE).Hydroxyl-attached carbon peaks at 156.87 and 161.91 ppm exhibited downfield shifts relative to pure RES (154.8, 161.5 ppm), confirming hydrogen bonding interactions in the solid state. The aromatic region (145.94 and 147.56 ppm) also showed small but significant shifts, supporting the presence of π-π stacking interactions between RES and QUE in the cocrystal lattice. The consistency between solution-state and solid-state NMR data further strengthens the findings, providing conclusive evidence of cocrystal through hydrogen bonding and π-π stacking interactions. Solubility studies Two distinct pH solutions (1.2 and 6.8) that correspond to the stomach and intestines, respectively, were used for the solubility studies. The solubility of was trans- resveratrol found to be higher at intestinal pH than at gastric pH (Fig. 7A). The solubility of trans-resveratrol from RES-QUE CoCry (173.70 ± 6.3 µg/ml) in phosphate buffer solution with 6.8 pH, from RES-QUE (82.5 ± 8.3 µg/mL) and from pure RES (79.5 ± 3.34 µg/mL). Similarly, the solubility of trans-resveratrol from RES-QUE CoCry (94.5 ± 3.3 µg/mL) at 1.2 pH, from RES-QUE (63.48 ± 6.4 µg/mL), from pure RES (59.3 ± 2.12 µg/mL). The solids obtained after equilibrium time were subjected to PXRD studies to check for any changes in solid state (Fig. 7B), revealed an excellent peak to peak match for the cocrystals after solubility . Fig. 7(A) Solubility profiles of RES (pure resveratrol), RES-QUE (physical mixture of resveratrol and quercetin), and RES-QUE CoCry (cocrystal of resveratrol and quercetin) in simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8). (B) Solid-state characterization of RES-QUE CoCry at solubility equilibrium, showing the before state (black line) and post-equilibrium state (red line).The peak-to-peak match between the PXRD patterns before and after solubility assessment confirms the structural integrity of the cocrystal. This indicates that the cocrystal maintained its crystalline form during dissolution, demonstrating its physical stability under the tested conditions.” (A) Solubility profiles of RES (pure resveratrol), RES-QUE (physical mixture of resveratrol and quercetin), and RES-QUE CoCry (cocrystal of resveratrol and quercetin) in simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8). (B) Solid-state characterization of RES-QUE CoCry at solubility equilibrium, showing the before state (black line) and post-equilibrium state (red line).The peak-to-peak match between the PXRD patterns before and after solubility assessment confirms the structural integrity of the cocrystal. This indicates that the cocrystal maintained its crystalline form during dissolution, demonstrating its physical stability under the tested conditions.” Dissolution studies The cumulative dissolution rate was determined for the pure RES and RES-QUE CoCry obtained by solvent evaporation. The dissolution rate was determined in 0.1 N HCL(1.2pH) and phosphate buffer solution (6.8 pH) as bio relevant dissolution media and the results are presented (Fig. 8). Cumulative percent of dissolution at 1.2 pH was reported as RES-38.6%, and RES-QUE CoCry − 80.9% after 2 h. The dissolution rate of the RES at 6.8 pH increased slowly and reached 51% within 2 h, whereas that of the cocrystals increased quickly, reaching 95.02%. The increase in the dissolution rate of the RES-QUE CoCry is because of the change in the crystal morphology. Fig. 8Dissolution profiles of RES (pure resveratrol) and RES-QUE CoCry (cocrystal of resveratrol and quercetin) in (A) simulated gastric fluid (pH 1.2) and (B) simulated intestinal fluid (pH 6.8), demonstrating significantly enhanced dissolution of the cocrystal in both media. Dissolution profiles of RES (pure resveratrol) and RES-QUE CoCry (cocrystal of resveratrol and quercetin) in (A) simulated gastric fluid (pH 1.2) and (B) simulated intestinal fluid (pH 6.8), demonstrating significantly enhanced dissolution of the cocrystal in both media. Permeability studies by everted sac method The use of an everted sac model to study the permeability of RES and its cocrystals with QUE across the jejunum of rat intestines. The apparent permeability (Papp) value was determined using a periodical sample collection taken from inside of the sac. The Papp of RES was found to be 0.0318 × 10− 6where as the Papp of RES-QUE and RES-QUE CoCry were found to be as 0.0502 × 10−6 and 0.0841 × 10−6 cm/s respectively. The concentration of trans-resveratrol permeated through intestinal sac at different time points from RES, RES-QUE, RES-QUE CoCry was represented (Fig. 9). The substantial increase in RES permeability from RES-QUE and RES-QUE CoCry can be attributed not only to improved solubility but critically to the presence of quercetin (QUE), inhibitor of intestinal efflux transporters including P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). These transporters normally limit RES absorption by actively pumping it back into the intestinal lumen. By inhibiting P-gp and BCRP, QUE effectively reduces RES efflux, thereby enhancing its net absorption. Fig. 9Apparent permeability (Papp) of RES (pure resveratrol), RES-QUE (physical mixture of resveratrol and quercetin), and RES-QUE CoCry (cocrystal of resveratrol and quercetin) determined by the everted sac method, showing a marked improvement in permeability for the cocrystal compared to the pure drug and physical mixture. Apparent permeability (Papp) of RES (pure resveratrol), RES-QUE (physical mixture of resveratrol and quercetin), and RES-QUE CoCry (cocrystal of resveratrol and quercetin) determined by the everted sac method, showing a marked improvement in permeability for the cocrystal compared to the pure drug and physical mixture. Stability studies After three months of stability period the stored sample was subjected to powder X-ray diffraction (PXRD) analysis and revealed no significant changes in the diffraction patterns compared to the initial measurements, indicating that the crystalline structure remained stable over the storage period. Stability indicating XRD diffraction patterns are presented in (Fig. 10). Fig. 10Stability studies of RES-QUE CoCry (cocrystal of resveratrol and quercetin): (A) before three months of storage and (B) after three months of storage, showing no significant changes in the solid-state profile, indicating good physical stability under the tested conditions. Stability studies of RES-QUE CoCry (cocrystal of resveratrol and quercetin): (A) before three months of storage and (B) after three months of storage, showing no significant changes in the solid-state profile, indicating good physical stability under the tested conditions. Pharmacokinetic study The pharmacokinetics of RES and its cocrystal were evaluated in rat plasma using the HPLC method. Plasma samples were collected following oral administration of pure RES (10 mg/kg) and an equivalent dose of RES-QUE and RES-QUE CoCry. A single-dose, 24-hour pharmacokinetic study was conducted in-vivo. The extraction procedure of RES from rat plasma is illustrated in (Fig. 11A), while the mean plasma concentration–time curves for pure RES, RES-QUE, and RES-QUE CoCry are shown in Fig. 11B. Pharmacokinetic parameters, summarized in (Table 2), were determined using a non-compartmental model(NCA) with WinNonlin software (Version 8.3 ). The results indicate that rats treated with RES-QUE CoCry exhibited significantly higher plasma concentrations of RES compared to those receiving RES-QUE and pure RES. The maximum plasma concentration (Cmax) of RES was 404.8 ± 15.5 ng/mL for RES-QUE CoCry, 238.4 ± 16.3 ng/mL for RES-QUE, and 125.7 ± 7.5 ng/mL for pure RES. The Cmax of RES was significantly higher in the RES-QUE CoCry group compared to both RES-QUE (p < 0.01) and pure RES (p < 0.001), indicating enhanced absorption. Additionally, the time to reach maximum concentration (Tmax) was significantly prolonged in the RES-QUE CoCry group (p < 0.05) compared to pure RES, suggesting a modified release profile. The area under the plasma concentration-time curve from 0 to 24 h (AUC0 − 24 h) was also significantly higher in the RES-QUE CoCry group (1809 ± 120.53 ng*h/ml) compared to RES-QUE (1173 ± 115 ng*h/mL) (p < 0.05), and pure RES (523 ± 84.25 ng*h/mL) (p < 0.001), suggesting enhanced bioavailability of RES in its cocrystal form. Half-life (t1/2), mean residence time (MRT), and elimination rate constant (Kₑ), remained unchanged. Fig. 11(A) HPLC chromatogram of rat plasma showing resveratrol (retention time: 3.78 min) and the internal standard verapamil (retention time: 5.133 min). (B) Pharmacokinetic profiles of RES (pure resveratrol) treated, RES-QUE (physical mixture of resveratrol and quercetin) treated, and RES-QUE CoCry (cocrystal of resveratrol and quercetin) treated, demonstrating improved systemic exposure for the cocrystal compared to the pure drug and physical mixture. (A) HPLC chromatogram of rat plasma showing resveratrol (retention time: 3.78 min) and the internal standard verapamil (retention time: 5.133 min). (B) Pharmacokinetic profiles of RES (pure resveratrol) treated, RES-QUE (physical mixture of resveratrol and quercetin) treated, and RES-QUE CoCry (cocrystal of resveratrol and quercetin) treated, demonstrating improved systemic exposure for the cocrystal compared to the pure drug and physical mixture. Table 2Pharmacokinetic data of trans-resveratrol in rat plasma.Pk parametersRESRES-QUERES-QUE CoCryCmax(ng/mL)125.6 ± 12.2238 ± 16.5*404 ± 15.2***t1/2(hr)6.7 ± 1.26.72 ± 3.46.91 ± 2.71tmax(hr)0.5 ± 0.121 ± 0.381 ± 0.24AUC0 − 24 h(ng*h/mL)523.7 ± 84.251173.5 ± 115*1809.19 ± 212.12***CL/F(L/hr/kg)4.76 ± 1.042.10 ± 0.781.38 ± 0.21Vd /F(L/Kg)52.5 ± 10.2\20.78 ± 7.4413.78 ± 2.24MRT( hr)9.72 ± 2.28.8 ± 2.149.07 ± 3.3Ke hr− 10.1034 ± 0.005 h− 10.1031 ± 003 h− 10.1003 ± 0.002 h− 1* p < 0.05,** p < 0.01, *** p < 0.001 compared with RES group. Data expressed as Mean ± SD (N = 4). RES (pure resveratrol), RES-QUE (physical mixture) and RES-QUE CoCry (cocrystal of resveratrol and quercetin) Cmax-Maximum concentration in plasma, Thalf -half life, Tmax-Time to reach maximal plasma concentration, AUC-Area Under the Concentration -Time curve, CL/F-Total plasma clearance, Vd /F-Volume of distribution, sMRT – Mean Residence Time, Ke- elimination rate constant. Table 2Pharmacokinetic data of trans-resveratrol in rat plasma.Pk parametersRESRES-QUERES-QUE CoCryCmax(ng/mL)125.6 ± 12.2238 ± 16.5*404 ± 15.2***t1/2(hr)6.7 ± 1.26.72 ± 3.46.91 ± 2.71tmax(hr)0.5 ± 0.121 ± 0.381 ± 0.24AUC0 − 24 h(ng*h/mL)523.7 ± 84.251173.5 ± 115*1809.19 ± 212.12***CL/F(L/hr/kg)4.76 ± 1.042.10 ± 0.781.38 ± 0.21Vd /F(L/Kg)52.5 ± 10.2\20.78 ± 7.4413.78 ± 2.24MRT( hr)9.72 ± 2.28.8 ± 2.149.07 ± 3.3Ke hr− 10.1034 ± 0.005 h− 10.1031 ± 003 h− 10.1003 ± 0.002 h− 1* p < 0.05,** p < 0.01, *** p < 0.001 compared with RES group. Data expressed as Mean ± SD (N = 4). RES (pure resveratrol), RES-QUE (physical mixture) and RES-QUE CoCry (cocrystal of resveratrol and quercetin) Cmax-Maximum concentration in plasma, Thalf -half life, Tmax-Time to reach maximal plasma concentration, AUC-Area Under the Concentration -Time curve, CL/F-Total plasma clearance, Vd /F-Volume of distribution, sMRT – Mean Residence Time, Ke- elimination rate constant. Pharmacokinetic data of trans-resveratrol in rat plasma. * p < 0.05,** p < 0.01, *** p < 0.001 compared with RES group. Data expressed as Mean ± SD (N = 4). RES (pure resveratrol), RES-QUE (physical mixture) and RES-QUE CoCry (cocrystal of resveratrol and quercetin) Cmax-Maximum concentration in plasma, Thalf -half life, Tmax-Time to reach maximal plasma concentration, AUC-Area Under the Concentration -Time curve, CL/F-Total plasma clearance, Vd /F-Volume of distribution, sMRT – Mean Residence Time, Ke- elimination rate constant. Anti-cancer activity of cocrystals Histopathology Histological analysis of intestinal tissues from different experimental groups provides critical insights into the protective effects of RES, RES-QUE, and RES-QUE CoCry. As observed in the microscopic images (Fig. 12A–E), the control group exhibited normal epithelial architecture with well-organized crypts and minimal inflammatory infiltration. In contrast, the MNU model group demonstrated severe tissue damage, characterized by disrupted crypt structure, extensive inflammatory cell infiltration, and epithelial erosion. Treatment with pure resveratrol (MNU + RES) resulted in partial tissue recovery, as seen in the restoration of crypt integrity, though inflammation was still noticeable. The combination of resveratrol and quercetin (MNU + RES-QUE) further improved epithelial architecture, reducing inflammation and tissue disruption compared to RES alone. Notably, the MNU + RES-QUE CoCry group exhibited the most significant histological recovery, with near-normal tissue morphology, reduced inflammatory cell infiltration, and preserved crypt structure, indicating superior therapeutic potential. A bar diagram (Fig. 12F) showing ACF count across various groups. The MNU model group displayed the highest ACF count, whereas treatment with RES and RES-QUE significantly reduced ACF scores. The RES-QUE CoCry group showed the most pronounced reduction in ACF number, suggesting that cocrystallization enhances the therapeutic efficacy of resveratrol and quercetin. This aligns with previous findings that cocrystallization can improve the solubility, bioavailability, and pharmacological effectiveness of active pharmaceutical ingredients. Fig. 12Histopathological examination of rat colon: (A) Control – section without aberrant crypt foci (ACF); (B) MNU-induced – section with numerous ACF, darkly stained with smaller lumens; (C) RES-treated – section showing typical nuclei within crypts, elongated ACF compared to normal crypts, and vacuolar degeneration between crypts; (D) RES-QUE-treated – section with moderately elongated crypts resembling ACF, with some crypts appearing normal; (E) RES-QUE CoCry-treated – section showing fewer lesions of pathological significance, indicating protective effects of the cocrystal. (F) A bar diagram showing ACF count across various groups. Data are expressed as Mean ± SD (N = 3). The reductions in ACF for the RES, RES-QUE, and RES-QUE CoCry groups were significant compared to the MNU-induced group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MNU-induced group. Histopathological examination of rat colon: (A) Control – section without aberrant crypt foci (ACF); (B) MNU-induced – section with numerous ACF, darkly stained with smaller lumens; (C) RES-treated – section showing typical nuclei within crypts, elongated ACF compared to normal crypts, and vacuolar degeneration between crypts; (D) RES-QUE-treated – section with moderately elongated crypts resembling ACF, with some crypts appearing normal; (E) RES-QUE CoCry-treated – section showing fewer lesions of pathological significance, indicating protective effects of the cocrystal. (F) A bar diagram showing ACF count across various groups. Data are expressed as Mean ± SD (N = 3). The reductions in ACF for the RES, RES-QUE, and RES-QUE CoCry groups were significant compared to the MNU-induced group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. MNU-induced group. RT-qPCR The expression of the anti-apoptotic BCL2 gene was analyzed across all treatment groups using quantitative real-time PCR (qRT-PCR) and evaluated by the ΔCq method shown in (Fig. 13). Fold change values were calculated using the 2–ΔCq formula shown in Table 3. The MNU-induced model group showed a marked upregulation (fold change = 8.26, ΔΔCq = − 3.0367, p < 0.01) compared to the control, indicating strong induction of the target gene. Treatment with resveratrol alone (MNU + RES) resulted in a slight, non-significant reduction (fold change = 1.12, ΔΔCq = – 0.1667, p > 0.05). However, the combination of resveratrol and quercetin (MNU + RES + QUE) significantly down regulated expression (fold change = 0.02, ΔΔCq = 5.6533, p < 0.01), suggesting a synergistic effect. Most notably, the resveratrol–quercetin cocrystal (MNU + RES–QUE CoCry) exhibited the strongest suppression (fold change = 0.0005, ΔΔCq = 10.7533, p < 0.001), indicating superior efficacy of the cocrystal formulation in mitigating gene expression associated with the pathological condition. Fig. 13RT-qPCR analysis for estimation of BCL2 gene expression: (A) amplification plot for the housekeeping gene GAPDH, (B) amplification plot for the target gene BCL2, and (C) bar graph showing ΔCq values for BCL2 expression across experimental groups, indicating down regulation of BCL2 in the RES-QUE CoCry-treated group compared to controls. RT-qPCR analysis for estimation of BCL2 gene expression: (A) amplification plot for the housekeeping gene GAPDH, (B) amplification plot for the target gene BCL2, and (C) bar graph showing ΔCq values for BCL2 expression across experimental groups, indicating down regulation of BCL2 in the RES-QUE CoCry-treated group compared to controls. Table 3Relative expression levels of BCL2 among treatment groups vs. MNU Model.*P < 0.05, significant reduction in BCL2 expression, ** p < 0.01-more significant reduction in BCL2, *** P < 0.001- highly significant.GroupMean ΔCqΔΔCq(vs. Control)Fold ChangeCONTROL1.046701.00MNU Model–1.99-3.03678.265MNU + RES0.88-0.16671.12*MNU + RES-QUE6.75.65330.02**MNU + RES-QUE CoCry11.8010.75330.0005*** Table 3Relative expression levels of BCL2 among treatment groups vs. MNU Model.*P < 0.05, significant reduction in BCL2 expression, ** p < 0.01-more significant reduction in BCL2, *** P < 0.001- highly significant.GroupMean ΔCqΔΔCq(vs. Control)Fold ChangeCONTROL1.046701.00MNU Model–1.99-3.03678.265MNU + RES0.88-0.16671.12*MNU + RES-QUE6.75.65330.02**MNU + RES-QUE CoCry11.8010.75330.0005*** Relative expression levels of BCL2 among treatment groups vs. MNU Model.*P < 0.05, significant reduction in BCL2 expression, ** p < 0.01-more significant reduction in BCL2, *** P < 0.001- highly significant. Western blot analysis For the quantitative analysis of BCL2, an anti-apoptotic protein, expression, the chemiluminescent Western blot images were captured and subjected to densitometric analysis using ImageJ software (NIH, Bethesda, MD). Specifically, the Integrated Density Value (IDV) of each protein band was calculated after subtracting the local background signal, ensuring that all measurements were linear and within the detection range. To correct for variations in protein loading, the IDV of the target protein, BCL2 (26 kDa), was normalized to the IDV of the corresponding β-actin (41 kDa) band for each sample. The final normalized values for all treatment groups were then calculated (Fig. 14). Densitometry analysis showed marked up regulation of BCL2in MNU model rats (4.39 ± 0.35) compared to control (1.45 ± 0.12, p < 0.001). Resveratrol treatment (MNU + RES) partially suppressed BCL2 expression (1.86 ± 0.18, *p < 0.05 vs. MNU model), while the combination with quercetin (MNU + RES-QUE) resulted in further down regulation (0.62 ± 0.10, **p < 0.01 vs. MNU model). The resveratrol–quercetin cocrystal (MNU + RES-QUE CoCry) showed the most pronounced suppression (0.33 ± 0.08, ***p < 0.001 vs. MNU model), indicating enhanced efficacy via cocrystal formation (Table 4). Inclusion of mean ± SD values demonstrates reproducibility and strengthens confidence in the observed effects. Fig. 14(A) Western blot analysis for estimation of BCL2 protein expression, using β-actin as the reference control. 1 = Control,2 = MNU model,3 = MNU+RES,4 =MNU+ RES-QUE,5 = MNU+RES-QUE CoCry. (B) Quantitative analysis of BCL2 protein expression levels normalized to β-actin, showing reduced BCL2 expression in the RES-QUE CoCry-treated group compared to controls.(Full-length blots are provided in Supplementary Figure S1). (A) Western blot analysis for estimation of BCL2 protein expression, using β-actin as the reference control. 1 = Control,2 = MNU model,3 = MNU+RES,4 =MNU+ RES-QUE,5 = MNU+RES-QUE CoCry. (B) Quantitative analysis of BCL2 protein expression levels normalized to β-actin, showing reduced BCL2 expression in the RES-QUE CoCry-treated group compared to controls.(Full-length blots are provided in Supplementary Figure S1). Table 4Normalized BCL2 protein expression (mean ± SD, n = 3) in different experimental groups.GroupNormalized BCL2 (Mean ± SD)InterpretationControl1.45 ± 0.12Baseline anti-apoptotic activity (normal control)MNU model4.39 ± 0.35Strong upregulation due to MNU induction (carcinogenic state)MNU + RES1.86 ± 0.18*Moderate reduction by resveratrol (pro-apoptotic effect)MNU + RES-QUE0.62 ± 0.10**Further suppression by resveratrol + quercetin (synergistic)MNU + RES-QUE CoCry0.33 ± 0.08***Most potent downregulation (enhanced efficacy via cocrystal)Control represented baseline levels; MNU model showed upregulation due to carcinogen; MNU + RES shown partial suppression by resveratrol; MNU + RES-QUE shown further down regulation by resveratrol + quercetin; MNU + RES-QUE CoCry demonstrated maximal suppression via cocrystal. Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). Table 4Normalized BCL2 protein expression (mean ± SD, n = 3) in different experimental groups.GroupNormalized BCL2 (Mean ± SD)InterpretationControl1.45 ± 0.12Baseline anti-apoptotic activity (normal control)MNU model4.39 ± 0.35Strong upregulation due to MNU induction (carcinogenic state)MNU + RES1.86 ± 0.18*Moderate reduction by resveratrol (pro-apoptotic effect)MNU + RES-QUE0.62 ± 0.10**Further suppression by resveratrol + quercetin (synergistic)MNU + RES-QUE CoCry0.33 ± 0.08***Most potent downregulation (enhanced efficacy via cocrystal)Control represented baseline levels; MNU model showed upregulation due to carcinogen; MNU + RES shown partial suppression by resveratrol; MNU + RES-QUE shown further down regulation by resveratrol + quercetin; MNU + RES-QUE CoCry demonstrated maximal suppression via cocrystal. Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). Normalized BCL2 protein expression (mean ± SD, n = 3) in different experimental groups. Control represented baseline levels; MNU model showed upregulation due to carcinogen; MNU + RES shown partial suppression by resveratrol; MNU + RES-QUE shown further down regulation by resveratrol + quercetin; MNU + RES-QUE CoCry demonstrated maximal suppression via cocrystal. Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001). Discussion Molecular docking predicts the type of interaction between molecules by simulating docking poses to identify binding sites and conformations. This approach helps select coformers with favorable interactions for stable cocrystal formation37. Docking results suggested that RES and QUE form stable intermolecular interactions primarily through hydrogen bonding and π-π stacking, facilitating cocrystal formation. A 1:1 molar ratio of RES and QUE was chosen based on the synthons approach to ensure optimal hydrogen bonding for stability and reproducibility38. Complementary functional groups in RES and QUE form stable supramolecular synthons via O–H⋯O interactions. FTIR analysis confirmed these interactions, indicating successful cocrystal formation. FTIR of RES-QUE CoCry showed shifts in RES aromatic C = C and QUE C = O bands (1655 → 1662 cm−1), indicating hydrogen bonding and non-covalent interactions39. DSC analysis showed that QUE exhibited a melting peak at 323.1 °C and a broad endothermic peak at 135.8 °C for water loss, consistent with literature40. The RES-QUE physical mixture displayed eutectic melting at 256.52 °C, whereas RES-QUE CoCry showed a single endothermic peak at 268.10 °C, indicating cocrystal formation, purity, and absence of unreacted solvent. The cocrystal’s melting point lies between those of RES and QUE, consistent with previous reports41. PXRD analysis showed distinct characteristic peaks for RES and QUE, confirming their individual crystallinity, similar to reported values42,43.The RES-QUE physical mixture displayed peaks of both compounds, indicating mere coexistence without structural changes44. In contrast, RES-QUE CoCry exhibited new diffraction peaks, providing clear evidence of a new crystalline phase and validating molecular docking predictions. SEM analysis supported these findings, showing distinct morphological differences between pure compounds, physical mixture, and cocrystal, further indicating molecular interaction45. The 13C NMR spectra of RES-QUE CoCry showed the presence of resonance peaks from the RES and QUE with significant chemical shift indicating the formation of new phase significant, evidenced from reported studies46. Notably, the carbonyl (C = O) peak at 175.98 ppm in the cocrystal exhibited a downfield shift compared to pure QUE (175.2 ppm)47, suggesting the presence of a strong hydrogen bond network reinforcing cocrystal stability. Hydroxyl Carbon (C-OH) at 164.16 ppm shifts upfield from QUE (164.8 ppm), suggesting electron redistribution due to new H-bonding interactions48. The minor shifts in aromatic regions suggest that π-π stacking and hydrogen bonding plays key roles in cocrystal stabilization. From 1H solution NMR spectra, hydroxyl (-OH) protons (12.50, 10.91, and 9.53 ppm) exhibited downfield shifts compared topure RES (9.51 ppm) and QUE (12.48, 10.89 ppm)49 and QUE (12.48, 10.89 ppm)50. Aromatic proton region (6.2–8.0 ppm) remains largely unchanged, indicating that the core aromatic system is preserved in the cocrystal. The formation of a unique cocrystal structure was validated by solid-state characterization using 13C CP/MAS NMR spectroscopy. The detected chemical shifts at 173.941, 163.510, 156.877, and 147.558 ppm refer to changes in the carbon nuclei’s electronic environment, which is suggestive of robust intermolecular interactions between RES and QUE. The downfield shift in both solution (175.98 ppm) and SSNMR (173.941 ppm) suggests stronger hydrogen bonding of the carbonyl group in the cocrystal compared to pure QUE. The shift is more pronounced in solution-state NMR, likely due to solvent interactions, while SSNMR reflects solid-state hydrogen bonding stabilizing the cocrystal structure. Solution-state NMR shows an upfield shift (164.8 → 164.16 ppm), suggesting increased electron density, possibly due to H-bond stabilization. SSNMR (163.348 → 163.510 ppm) exhibits a slight downfield shift, reflecting structural rigidity and reduced molecular motion in the solid state. This supports hydrogen bonding-driven stabilization in the cocrystal, where hydroxyl groups interact more strongly in the solid state. The results of the solubility analysis demonstrated that RES-QUE CoCry was much more soluble than the physical combination and pure trans-resveratrol at both pH 6.8 (173.70 ± 6.3 µg/mL) and pH 1.2 (94.5 ± 3.3 µg/mL). Solubility studies showed that RES-QUE CoCry was significantly more soluble than the physical mixture or pure RES, at both pH 6.8 (173.70 ± 6.3 µg/mL) and pH 1.2 (94.5 ± 3.3 µg/mL), with over a twofold increase at pH 6.8. Enhanced solubility is attributed to changes in intermolecular interactions, crystal morphology, and wettability, resulting in a higher dissolution rate42,51. Permeability was increased 2.64 fold, suggesting improved bioavailability, possibly due to reduced lattice energy and QUE-mediated inhibition of efflux transporters52.The pharmacokinetic investigation showed that the bioavailability of resveratrol was greatly increased by RES-QUE CoCry. Superior absorption and systemic exposure were indicated by the 3.2-fold rise in Cmax and the 3.5-fold improvement in AUC0-24 h. Prolonged systemic retention was suggested by the decrease in clearance (CL/F). For RES-QUE CoCry, the tmax was marginally postponed to 1 h, suggesting altered absorption kinetics. The MRT, Ke, and t1/2 did not change, indicating that the elimination processes were unaltered53. Histological evaluation (Fig. 12A–E) revealed severe tissue damage in the induced group (MNU model), characterized by crypt disruption and inflammation. RES treatment showed partial recovery, while RES-QUE improved epithelial integrity further. Notably, RES-QUE CoCry exhibited the most significant restoration, with preserved crypt structure and minimal inflammation.ACF analysis (Fig. 12F) confirmed that RES-QUE CoCry showed the greatest reduction in tissue damage, indicating enhanced therapeutic potential. In this colorectal cancer model, the MNU model group exhibited a marked upregulation of BCL2, reflecting enhanced tumor cell survival. Treatment with RES significantly down regulated BCL2, consistent with its pro-apoptotic and anti-inflammatory properties54. Combination of RES and QUE also showed more down regulation55. Notably, RES-QUE CoCry the achieved the most pronounced reduction in BCL2 expression, indicating improved bioavailability and therapeutic efficacy. The significant upregulation of BCL2 in the MNU-induced group reflects enhanced anti-apoptotic activity typical of carcinogenic progression. Resveratrol (RES) treatment moderately reduced BCL2 levels, consistent with its reported pro-apoptotic effects in cancer models56. Co-administration with quercetin (RES-QUE) further suppressed BCL2 expression, suggesting additive or synergistic interactions. Notably, the resveratrol-quercetin cocrystal (RES-QUE CoCry) demonstrated the most pronounced down regulation of BCL2, indicating superior pro-apoptotic and therapeutic efficacy. This enhanced effect may be attributed to improved solubility and bioavailability associated with cocrystallization .These findings support the potential of cocrystal formulations to enhance the pharmacological profile of natural compounds in chemoprevention. These results highlight the potential of cocrystallization as a promising strategy to enhance the anticancer activity of natural compounds in colorectal cancer treatment. Conclusion This study demonstrates that cocrystallization is an effective strategy for enhancing the physicochemical and pharmacokinetic properties of resveratrol. A multi-faceted approach, combining molecular docking with various analytical techniques, confirmed the successful formation of the RES–QUE cocrystal. Cocrystal was shownenhanced solubility, dissolution, permeability, and bioavailability compared to pure resveratrol. Pharmacokinetic and biological analyses demonstrated improved systemic exposure and anticancer activity, highlighting its potential for colorectal cancer therapy. However, the clinical translation of cocrystals requires careful consideration of scalability and manufacturability, as reproducible large-scale production, control over crystal form, and stability under varying conditions are critical for regulatory approval and practical application. Future studies should validate these results in scalable manufacturing processes, alternative preclinical models, assess long-term safety, and explore clinical translation to confirm the therapeutic benefits in human. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1